Athos Gianella-Borradori, M.D. has been appointed chief medical officer of Chugai Pharma USA, LLC, a subsidiary of Chugai Pharmaceutical Co. of Tokyo, Japan, and member of the Roche Group.
 
Dr. Gianella-Borradori is pediatric hematologist-oncologist and executive with more than 20 years of international R&D experience focusing on translational research and clinical development of novel therapeutics. He has held senior R&D positions at Novartis, Crucell, Bavarian Nordic, Cyclacel, Merck Serono, and Clavis Pharma. 
 
Dr. Gianella-Borradori is responsible for all clinical activity in the U.S. and will provide leadership for scientific and translational committees in Japan at the parent company. He represents the company in relationships with the FDA, academia, clinical investigators and patient communities, and is responsible for increasing the awareness of Chugai to facilitate its expanding clinical activity in the U.S.